Been on doxycycline or minocycline for months with barely a dent in your breakouts? There's a well-documented reason this happens, and it has nothing to do with dosage or how consistent you've been.

Quick answer: Gram-negative folliculitis is a bacterial skin condition that develops after long-term antibiotic use for acne or rosacea and is frequently mistaken for regular acne. Standard acne antibiotics don't treat it, and can make it worse. A skin microbiome test that uses whole-genome sequencing, rather than a standard bacterial culture, is the most reliable way to identify it and get to the right treatment faster.

What Gram-Negative Folliculitis Actually Is

Gram-negative folliculitis (GNF) is a bacterial skin condition first documented in the dermatology literature in 1968. It shows up almost exclusively in people already being treated for acne or rosacea with long-term oral antibiotics, and the organisms behind it are ones most people never associate with a breakout: Escherichia coli, Pseudomonas aeruginosa, Serratia marcescens, Klebsiella, Staph aureus, and Proteus mirabilis.

The mechanism has been understood for decades. Tetracyclines and similar antibiotics suppress the gram-positive bacteria that normally occupy the nose and face. That decline opens a niche, and gram-negative bacteria fill it, spreading from the nasal passages to the rest of the face. Roughly 80% of cases show up as widespread superficial pustules driven by Klebsiella, E. coli, or Serratia. The remaining 20 percent involve deeper, nodular, cyst-like lesions caused by Proteus species invading further into the follicle.

Clinically, GNF looks a lot like ordinary acne. That resemblance is a large part of why it gets missed.

Signs a Flare Might Be Gram-Negative, Not Acne

A few patterns tend to show up in gram-negative folliculitis that don't fit the usual acne picture:

• The breakout appeared or worsened while already taking an oral antibiotic for acne or rosacea
• 3-6 months of tetracycline-class treatment (doxycycline, minocycline) produced little to no improvement
• Pustules are uniform and clustered around the nose, upper lip, chin, and cheeks rather than scattered across the usual acne zones
• A prior flare that responded to antibiotics has come back looking different, often more pustular and less cystic
• Standard topical acne treatments (benzoyl peroxide, retinoids, topical clindamycin) have made little difference

None of these on their own confirms gram-negative folliculitis. Together, they're a strong signal that the flare deserves a bacterial workup instead of another antibiotic course.

Why It Gets Mistaken for Acne, and Why That's a Problem

Dermatology guidance has long been direct about when to suspect gram-negative folliculitis: a flare of pustular or cystic lesions while already on antibiotics, or no meaningful improvement after 3-6 months of tetracycline therapy. Despite that guidance, a review by dermatologists Böni and Nehrhoff notes that bacterial culture is rarely ordered in practice, which is a large part of why the condition is considered widely underdiagnosed.

There is a concerning problem with missing folliculitis. When a flare that's actually gram-negative folliculitis gets treated as ordinary acne, the standard response is to add more of the same antibiotic class or push the dose higher. That approach doesn't touch gram-negative organisms, and it can clear even more room for them by further suppressing the gram-positive flora that would otherwise keep them in check. The flare worsens, the prescription runs longer, and the organism actually driving it is never identified. That pattern also feeds a larger issue researchers have raised: prolonged, broad-spectrum antibiotic use is a known driver of multidrug resistance among gram-negative bacteria, part of why interest in more targeted, bacteria-specific approaches has grown.

Why Testing Beats Guessing

Pustules from Cutibacterium acnes overgrowth, Staphylococcus, and gram-negative organisms can look nearly identical on the skin's surface. The only way to know which bacteria are actually driving a flare is to look at them directly, not to treat by category label.

Why Even a Culture Can Miss It

Ordering a bacterial culture sounds like the obvious fix, and it's a real step forward from guessing. But culture has its own blind spots. A 2023 review in Clinical Infectious Diseases points out that many bacteria are fastidious or slow-growing and don't thrive under standard lab conditions, and estimates of how much of the bacterial world resists routine culturing run surprisingly high. A fast-growing organism on the plate can also crowd out a slower one, so a culture can come back naming a single bacterium when more than one is actually present and contributing to the flare.

Researchers who sequenced bone and joint infection samples directly, rather than relying only on what grew in culture, identified over 270 bacteria across their sample set that standard culture had missed entirely, while still correctly predicting antibiotic susceptibility in the large majority of cases. The same limitation applies to skin. A culture reflects what happened to grow on that particular plate, not necessarily the full bacterial community actually living on the skin.

Where Whole-Genome Sequencing Changes the Picture

Whole-genome shotgun sequencing works differently. Instead of trying to grow anything, it reads the DNA present in the sample directly, so slow-growing, low-abundance, or unusual organisms show up in the results even when they wouldn't have survived on a culture plate. It also returns a relative abundance for every organism found, not a single yes-or-no answer, so the result shows how much gram-negative overgrowth is present relative to the flora that should be there.

That's what skin microbiome testing is built to do. A quantitative whole-genome sequencing panel from Parallel Health produces a Quantitative Microbial Analysis™ and Metabolic Microbiome Profiling™ instead of a visual guess or an incomplete culture. That result determines whether the right next step is a narrow, culture-directed antibiotic aimed at the specific organism found, or a precision-matched phage treatment developed to target that exact bacterial strain while leaving the rest of the skin's ecosystem intact. This is the premise behind Microbiome Dermatology™ where dermatologists at Parallel Health treat skin conditions based on which organisms are actually present rather than by symptom appearance or a single plate result.

The Bottom Line

Recurring pustules that resist antibiotics aren't a sign to try harder with the same drug. They're a sign to find out what's actually there. For anyone who has spent months treating stubborn "acne," or any skin issue for that matter, without real progress, a microbiome test is a faster route to an answer than another prescription refill.

Frequently Asked Questions

What is the difference between gram-negative folliculitis and regular acne?

Regular acne is driven largely by Cutibacterium acnes and clogged follicles. Gram-negative folliculitis is caused by organisms like Klebsiella, E. coli, Proteus, and Pseudomonas that move in after long-term antibiotic use disrupts the skin's normal gram-positive flora. The two can look identical without lab testing.

Why do antibiotics make gram-negative folliculitis worse instead of better?

Standard acne antibiotics target gram-positive bacteria. Continuing or increasing them removes more of the gram-positive flora that normally keeps gram-negative organisms in check, giving those bacteria more room to spread.

How is gram-negative folliculitis actually diagnosed?

Through bacterial culture or microbial sequencing of the affected skin, not by appearance alone. Only quantitative microbiome testing identifies which organisms are present and at what levels, which is what determines the correct treatment.

Is a bacterial culture enough to catch gram-negative folliculitis?

Not always. Many bacteria are slow-growing or fastidious and don't grow well on standard culture media, and a fast-growing organism can crowd out a slower one on the same plate. Whole-genome sequencing reads the DNA present in the sample directly, so it can pick up organisms a culture would miss and show their relative abundance.

Can gram-negative folliculitis be treated without more broad-spectrum antibiotics?

Yes. Once the specific organism is identified, options include a narrow, culture-directed antibiotic or a precision-matched phage treatment aimed only at that strain, leaving the rest of the skin microbiome undisturbed.

How long does it take to see results once the right cause is identified?

Because treatment is matched to the actual organism instead of chosen by trial and error, most people see a meaningfully faster response than they did on months of broad-spectrum antibiotics that were never going to work on a gram-negative organism. That being said, every bacterial community is different in the way it behaves. Our patients have typically started to see results within six months of use.

References

1. Fulton JE, McGinley K, Leyden JJ, Marples RR. Gram-negative folliculitis in acne vulgaris. Arch Dermatol. 1968;98(4):349-353.
2. Leyden JJ, Marples RR, Mills OH Jr, Kligman AM. Gram-negative folliculitis: a complication of antibiotic therapy in acne vulgaris. Br J Dermatol. 1973;88(6):533-538.
3. Gram-negative folliculitis. DermNet NZ. Available at: dermnetnz.org/topics/gram-negative-folliculitis
4. Böni R, Nehrhoff B. Treatment of gram-negative folliculitis in patients with acne. Am J Clin Dermatol. 2003;4(4):273-276. PMID: 12680804.
5. Zagaliotis P, Michalik-Provasek J, Gill JJ, Walsh TJ. Therapeutic bacteriophages for gram-negative bacterial infections in animals and humans. Pathog Immun. 2022;7(2):1-45. doi:10.20411/pai.v7i2.516.
6. Neubert U, Jansen T, Plewig G. Bacteriologic and immunologic aspects of gram-negative folliculitis: a study of 46 patients. Int J Dermatol. 1999;38(4):270-274.
7. Kullar R, Chisari E, Snyder J, Cooper C, Parvizi J, Sniffen J. Next-generation sequencing supports targeted antibiotic treatment for culture-negative orthopedic infections. Clin Infect Dis. 2023;76(2):359-364. doi:10.1093/cid/ciac733.
8. Ruppé E, Lazarevic V, Girard M, Mouton W, Ferry T, Laurent F, Schrenzel J. Clinical metagenomics of bone and joint infections: a proof of concept study. Sci Rep. 2017;7(1):7718. doi:10.1038/s41598-017-07546-5.